Indoco Remedies Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 3/6

Indoco Remedies kazançlarla iyi bir şekilde karşılanan, 0.48% cari getiriye sahip, temettü ödeyen bir şirkettir.

Anahtar bilgiler

0.5%

Temettü verimi

-0.03%

Geri Alım Getirisi

Toplam Hissedar Getirisi	0.4%
Gelecekteki Temettü Verimi	0.8%
Temettü Büyümesi	-2.7%
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	₹1.500
Ödeme oranı	14%

Son temettü ve geri alım güncellemeleri

Recent updates

Indoco Remedies Limited Just Missed Earnings And Its Revenue Numbers Were Weaker Than Expected

Oct 27

Earnings Troubles May Signal Larger Issues for Indoco Remedies (NSE:INDOCO) Shareholders

May 24

Earnings Miss: Indoco Remedies Limited Missed EPS By 56% And Analysts Are Revising Their Forecasts

Jan 26

Does Indoco Remedies (NSE:INDOCO) Have A Healthy Balance Sheet?

Jan 26

We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Indoco Remedies Limited's (NSE:INDOCO) CEO For Now

Sep 16

Here's Why Indoco Remedies (NSE:INDOCO) Can Manage Its Debt Responsibly

May 21

Indoco Remedies (NSE:INDOCO) Has Announced That It Will Be Increasing Its Dividend To ₹1.50

Aug 31

Indoco Remedies (NSE:INDOCO) Has Announced That It Will Be Increasing Its Dividend To ₹1.50

Jul 04

Indoco Remedies Limited's (NSE:INDOCO) Intrinsic Value Is Potentially 21% Below Its Share Price

Mar 09

What Percentage Of Indoco Remedies Limited (NSE:INDOCO) Shares Do Insiders Own?

Feb 22

Did You Miss Indoco Remedies' (NSE:INDOCO) 37% Share Price Gain?

Feb 07

Indoco Remedies Limited's (NSE:INDOCO) Stock is Soaring But Financials Seem Inconsistent: Will The Uptrend Continue?

Jan 17

Is Indoco Remedies (NSE:INDOCO) A Risky Investment?

Dec 27

Calculating The Intrinsic Value Of Indoco Remedies Limited (NSE:INDOCO)

Dec 06

What Type Of Shareholders Own The Most Number of Indoco Remedies Limited (NSE:INDOCO) Shares?

Nov 14

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: INDOCO şirketinin temettü ödemeleri son 10 yıldır dalgalı seyretti.

Büyüyen Temettü: INDOCO şirketinin temettü ödemeleri son 10 yıldır artış göstermektedir.

Piyasaya Karşı Temettü Getirisi

Indoco Remedies Piyasaya Karşı Temettü Getirisi

INDOCO temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (INDOCO)	0.5%
Pazarın Alt %25'i (IN)	0.2%
Pazarın En İyi %25'i (IN)	1.1%
Sektör Ortalaması (Pharmaceuticals)	0.7%
Analist tahmini (INDOCO) (3 yıla kadar)	0.8%

Önemli Temettü: INDOCO 'in temettüsü ( 0.48% ), Indian piyasasındaki temettü ödeyenlerin en alttaki %25'inden ( 0.25% ) daha yüksektir.

Yüksek Temettü: INDOCO 'in temettüsü ( 0.48% ), Indian piyasasındaki temettü ödeyenlerin en üst %25'ine ( 1.13% ) kıyasla düşüktür.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: Düşük ödeme oranı ( 14% ) sayesinde INDOCO 'un temettü ödemeleri kazançlarla tamamen karşılanmaktadır.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: INDOCO temettü ödüyor ancak şirketin serbest nakit akışı yok.

Indoco Remedies Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 3/6

Anahtar bilgiler

Son temettü ve geri alım güncellemeleri

Indoco Remedies Limited Declares Final Dividend for Financial Year Ended March 31, 2024

Indoco Remedies Limited Declares Final Dividend for the Financial Year Ended March 31, 2023

Indoco Remedies Limited Recommends Dividend for the Financial Year 2022-2023

Indoco Remedies Limited Declares Final Dividend for the Financial Year Ended March 31, 2022

Upcoming dividend of ₹2.25 per share

Indoco Remedies Limited Approves Dividend for the Financial Year 2021-2022

Recent updates

MD & Executive Director recently bought ₹4.6m worth of stock

Consensus EPS estimates fall by 78%

Indoco Remedies Limited Just Missed Earnings And Its Revenue Numbers Were Weaker Than Expected

Price target decreased by 9.0% to ₹324

Second quarter 2025 earnings released: ₹1.09 loss per share (vs ₹3.82 profit in 2Q 2024)

Indoco Remedies Limited to Report Q2, 2025 Results on Oct 24, 2024

Indoco Remedies Limited Receives Final ANDA Approval from the USFDA for Cetirizine Hydrochloride Tablets USP, 10 mg

Indoco Remedies Limited Declares Final Dividend for Financial Year Ended March 31, 2024

Dividend of ₹1.50 announced

Indoco Remedies Limited, Annual General Meeting, Sep 26, 2024

Indoco Remedies Limited, Annual General Meeting, Sep 26, 2024

Indoco Remedies Limited Receives Final ANDA Approval from the USFDA for Lofexidine Tablets 0.18 Mg with Competitive Generic Therapy Designation

Consensus EPS estimates fall by 20%

First quarter 2025 earnings released: EPS: ₹0.20 (vs ₹2.62 in 1Q 2024)

Indoco Remedies Limited to Report Q1, 2025 Results on Jul 23, 2024

MD & Executive Director recently bought ₹3.1m worth of stock

Indoco Remedies Receives Tentative ANDA Approval from USFDA for Canagliflozin and Metformin Hydrochloride Tablets

Now 21% overvalued

Joint MD & Executive Director recently bought ₹1.2m worth of stock

Earnings Troubles May Signal Larger Issues for Indoco Remedies (NSE:INDOCO) Shareholders

Consensus EPS estimates fall by 16%

Full year 2024 earnings: EPS misses analyst expectations

Now 24% overvalued

Indoco Remedies Limited to Report Q4, 2024 Results on May 16, 2024

Indoco Remedies Limited Announces Cessation of Divakar M. Gavaskar and Rajiv P. Kakodkar as Independent Directors, Effective Mach 31, 2024

Consensus EPS estimates fall by 27%

Earnings Miss: Indoco Remedies Limited Missed EPS By 56% And Analysts Are Revising Their Forecasts

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Indoco Remedies Limited to Report Q3, 2024 Results on Jan 23, 2024

Insufficient new directors

Indoco Remedies Limited to Report Q2, 2024 Results on Oct 19, 2023

Indoco Remedies Limited Declares Final Dividend for the Financial Year Ended March 31, 2023

Indoco Remedies Limited, Annual General Meeting, Sep 26, 2023

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Indoco Remedies Limited to Report Q1, 2024 Results on Jul 25, 2023

MD & Executive Director recently bought ₹6.4m worth of stock

MD & Executive Director recently bought ₹1.6m worth of stock

Indoco Remedies Limited (NSEI:INDOCO) agreed to acquire a 85% stake in Florida Pharmaceutical Products, Inc. from Contract Pharmacal Corp. for $4 million.

Consensus EPS estimates fall by 13%

Indoco Remedies Limited Recommends Dividend for the Financial Year 2022-2023

Full year 2023 earnings: EPS and revenues miss analyst expectations

Indoco Remedies Limited to Report Q4, 2023 Results on May 23, 2023

MD & Executive Director recently bought ₹669k worth of stock

Insufficient new directors

Consensus EPS estimates fall by 11%

Does Indoco Remedies (NSE:INDOCO) Have A Healthy Balance Sheet?

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Indoco Remedies Limited to Report Q3, 2023 Results on Jan 24, 2023

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Indoco Remedies Limited Announces Executive Changes

Indoco Remedies Limited to Report Q2, 2023 Results on Nov 10, 2022

Indoco Remedies Limited Declares Final Dividend for the Financial Year Ended March 31, 2022

Indoco Remedies Limited Announces Anacipher CRO Clears USFDA Inspection with Zero 483S

We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Indoco Remedies Limited's (NSE:INDOCO) CEO For Now

Upcoming dividend of ₹2.25 per share

Indoco Remedies Limited, Annual General Meeting, Sep 22, 2022

Indoco Remedies Limited (BSE:532612) agreed to acquire 26% stake in Kanakal Wind Energy Private Limited for INR 8.64 million.

First quarter 2023 earnings released: EPS: ₹4.19 (vs ₹4.30 in 1Q 2022)

Indoco Remedies Limited to Report Q1, 2023 Results on Aug 09, 2022

Here's Why Indoco Remedies (NSE:INDOCO) Can Manage Its Debt Responsibly

Indoco Remedies Limited Approves Dividend for the Financial Year 2021-2022

Full year 2022 earnings: Revenues and EPS in line with analyst expectations

Indoco Remedies Limited Approves Dividend for the Financial Year 2021-2022

Indoco Remedies Limited to Report Q4, 2022 Results on May 17, 2022

Third quarter 2022 earnings: EPS exceeds analyst expectations

Second quarter 2022 earnings released: EPS ₹4.52 (vs ₹2.78 in 2Q 2021)

Upcoming dividend of ₹1.50 per share

Indoco Remedies (NSE:INDOCO) Has Announced That It Will Be Increasing Its Dividend To ₹1.50

First quarter 2022 earnings released: EPS ₹4.30 (vs ₹1.85 in 1Q 2021)